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Background: Excess accumulation of visceral fat is a prominent risk factor for cardiovascular and metabolic
morbidity. While computed tomography (CT) is the gold standard to measure visceral adiposity, this is often not
possible for large studies - thus valid, but less expensive and intrusive proxy measures of visceral fat are required
such as dual-energy X-ray absorptiometry (DXA). Study aims were to a) identify a valid DXA-based measure of
visceral adipose tissue (VAT), b) estimate VAT heritability and c) assess visceral fat association with morbidity in
relation to body fat distribution.
Methods: A validation sample of 54 females measured for detailed body fat composition - assessed using CT, DXA
and anthropometry – was used to evaluate previously published predictive models of CT-measured visceral fat.
Based upon a validated model, we realised an out-of-sample estimate of abdominal VAT area for a study sample of
3457 female volunteer twins and estimated VAT area heritability using a classical twin study design. Regression and
residuals analyses were used to assess the relationship between adiposity and morbidity.
Results: Published models applied to the validation sample explained >80% of the variance in CT-measured
visceral fat. While CT visceral fat was best estimated using a linear regression for waist circumference, CT body
cavity area and total abdominal fat (R2 = 0.91), anthropometric measures alone predicted VAT almost equally well
(CT body cavity area and waist circumference, R2 = 0.86). Narrow sense VAT area heritability for the study sample
was estimated to be 58% (95% CI: 51-66%) with a shared familial component of 24% (17-30%). VAT area is strongly
associated with type 2 diabetes (T2D), hypertension (HT), subclinical atherosclerosis and liver function tests. In
particular, VAT area is associated with T2D, HT and liver function (alanine transaminase) independent of DXA total
abdominal fat and body mass index (BMI).
Conclusions: DXA and anthropometric measures can be utilised to derive estimates of visceral fat as a reliable
alternative to CT. Visceral fat is heritable and appears to mediate the association between body adiposity and
morbidity. This observation is consistent with hypotheses that suggest excess visceral adiposity is causally related to
cardiovascular and metabolic disease.
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Body fat distribution, particularly abdominal adiposity, is
strongly associated with a range of chronic metabolic
and cardiovascular morbidities. The abdomen includes
depots of both subcutaneous and visceral adipose tissue,
which are distinct tissues that present different gene
expression [1], endocrinological profiles [2] and patho-
genicity [3]. The detrimental effect of excess fat accumu-
lation is contingent on body fat distribution. Kim et al.
[3] have shown that the diabetic phenotype of obese lep-
tin knock out mice can be rescued by shifting fat storage
away from the viscera and into the subcutaneous depot.
The high ratio of subcutaneous to visceral fat in this
mouse model is in contrast to the familial partial forms
of lipodystrophy observed in humans, a pathology
characterised by a redistribution of adipose tissue to the
intra-abdominal region, giving rise to severe metabolic
abnormalities as a consequence. These extreme cases il-
lustrate the potent effect that adipose distribution can
have upon health [4,5]. The accumulation of visceral fat
may also play a role in the aetiology of cardiovascular
and metabolic disease.
Adiposity can be measured with a variety of techniques
such as dual-energy X ray absorptiometry (DXA), com-
puted tomography (CT) and magnetic resonance imaging
(MRI). In whole body composition analysis, CT is
regarded as the gold standard and as such has been used
extensively as a benchmark for the quantitative assessment
of subcutaneous and visceral adiposity. However, CT and
MRI are limited in large research studies due to cost [6]
and radiation exposure [7]. As such, there is a continued
effort to identify informative adiposity measures that are
safe, easily acquired and show robust correlation with CT-
measured visceral fat content [8-11].
Family and twin studies can be used to estimate the
heritability (the proportion of trait variance explained by
genetic factors) and the relative importance of genetic
and shared environmental factors in influencing pheno-
typic variance, by contrasting trait covariance between
relatives with degree of relatedness. Establishing the her-
itable basis of a trait is also an important consideration
prior to gene mapping studies [12].
The aims of this study are to 1) identify and estimate a
valid DXA and anthropometric based measures of vis-
ceral fat that can be used in this and future epidemio-
logical studies, 2) estimate the heritability and the
degree of shared familial environment that influences
visceral fat accumulation and 3) to assess whether asso-
ciation between body composition measures of adiposity
and morbidities can be fully explained by visceral fat.
We hypothesise that if visceral fat is causally related to
morbidity, we would expect visceral fat to remain associ-
ated with morbidity conditional upon all other measures
of body fat distribution.Methods
Subjects and data collection
St. Thomas’ Research Ethics Committee approved the
study (EC96/439 Twins UK) and all participants pro-
vided informed written consent. Participants were fe-
male volunteers enrolled in the TwinsUK resource,
originally established in 1992 to study the heritability of
osteoarthritis and osteoporosis in women, but subse-
quently healthy male and female twins have been
recruited (mainly via national advertisements) without
respect to any particular disease [13]. While the twins
are largely representative of the age-matched UK female
population [14], our findings relating to adiposity are re-
stricted to Caucasian women over 40 years old with a
BMI ≤ 35.
The validation sample comprised 54 female individuals
over the age of 40 years with both CT and DXA data,
but was otherwise unselected. Previously reported linear
regression models [10,11,15] and adiposity indices [8]
were assessed for this sample to identify the most pre-
dictive combination of DXA abdominal fat and anthro-
pometry measures required to estimate visceral fat. A
validated best-fit model was then used to realise an esti-
mate of abdominal visceral fat for a study sample of
3,457 female individuals (533 monozygotic twin pairs,
1102 dizygotic pairs, 187 singletons), where date-
matched DXA abdominal fat and anthropometric data
were available.
CT
Subjects were placed in the supine position and a truncal
CT scan was performed using a CT helical scanner (Bril-
liance CT component of the Philips Precedence SPECT/
CT system, Philips, Eindhoven, Netherlands) with slice
thickness set at 5 mm. The total cross sectional area
(CSA) was intersected at the level of the intervertebral
disc between lumbar vertebrae four and five (L4:L5). CT
scan were analysed using Osirix X imaging software,
version 3.7.1 (Pixmeo, Switzerland) to provide high-
resolution 3-dimensional images. The body cavity CSA
was obtained by tracing the outer contour of the abdom-
inal wall and adipose tissue within this area was identi-
fied as having an attenuation value between −190
and −30 Hounsfield units [16]. For the 54 subjects with
CT and DXA scan data (“validation sample” from here
on in), visceral fat was directly measured as a pixel count
using CT single slice area (VAT) (area). VAT area was
defined as (visceral pixel count)/(total body cavity pixel
count) × BC CSA. Single slice visceral fat area and volume
are highly correlated [17,18].
DXA
Baseline whole body DXA scans were performed for
3,457 female twins aged 40–80 years (“study sample” from
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bone densitometer (QDR-4500 W, Hologic, Massachusetts)
and analysed with QDR System Software Version 12.6
(Hologic, Inc., Massachusetts). The DXA scanner was cali-
brated daily with a spine phantom and weekly using the
step phantom as instructed by the manufacturer’s guide-
lines. The region of interest for body composition analysis
was manually defined in a similar manner to Bertin et al.
[8]. The abdominal region was delineated by an upper hori-
zontal border located at half of the distance between
acromions and external end of iliac crests and a lower
border determined by the external end of iliac crests, but
the lateral borders were delineated by the inner body wall
rather than laterally past any trunk soft tissue. DXA fat
mass from this abdominal region was recorded and abdom-
inal transverse internal and external diameters were mea-
sured as defined by Bertin et al. [8].
Anthropometry
Anthropometrical measurements for both the validation
and study samples were height, weight, BMI and waist cir-
cumference [14]. Waist circumference for the validation
sample was based upon the transverse circumference of CT
body scan image at the waist, while the study sample was a
tape measurement taken at the same time as the DXA scan.
CT images were used to measure for sagittal depth, body
cavity, subcutaneous fat and total abdominal fat cross sec-
tional areas, transverse internal and external diameters
(TID and TED respectively) and subcutaneous fat width
(SFW). Subcutaneous fat width (SFW) was estimated as
SFW= (TED – TID)/2, which was also used as an estimate
for skin fold as a calliper skin fold measure was not taken
for the TwinsUK sample. The 54 subjects were also mea-
sured for TED and TID (with SFW derived) using DXA
software to draw a horizontal line on the DXA image at the
upper most point of the iliac crest, which was converted
from pixel to mm length by multiplying by a constant of
2.048 (DXA software support, Vertec Scientific Limited).
Type 2 diabetes
Subjects were identified as type 2 diabetic (T2D) if they
were classified as hyperglycaemic for one or more of the
following diagnostics: fasting glucose serum concentra-
tion > 7 mmol/L, fasting 2 hour oral glucose tolerance
test > 11.1 mmol/L or glycosylated haemoglobin > 48
mmol/mol. Questionnaire data on physician diagnosis and
medication was also used to identify self-reported cases of
T2D (2010–2011). Fasting plasma glucose was measured
by enzymatic colorimetric slide assay (Johnson and Johnson
Clinical Diagnostic Systems, Amersham UK).
Hypertension
Blood pressure was measured twice using an automa-
tic blood pressure monitor (Omron Healthcare, Inc.,Bannockburn, IL) using data from the same visit as the
DXA scan. Individuals were classified as having hyperten-
sion (HT), if currently receiving anti-hypertensive medica-
tion and/or the repeated systolic/diastolic blood pressure
was greater than 140/90 mm Hg.
Carotid intima-media thickness
Carotid intima-media thickness (cIMT) was measured as
previously described by Cecelja et al. [19] and the quan-
titative trait was dichotomised at the 75th percentile as a
surrogate for subclinical atherosclerosis [20,21]. In brief,
the left and right carotid and femoral arteries were visu-
alized with B-mode ultrasound (Siemens CV70, Siemens,
Erlangen, Germany, with 13-MHz vascular probe). Com-
mon carotid IMT was measured in the near and far
walls, 1 to 2 cm proximal to the carotid bifurcation with
automated wall-tracking software (Medical Imaging Ap-
plications, Coralville, Iowa) during diastole in an area
free of overt plaque. Mean values of IMT in the near
and far walls of both arteries were used for analysis.
Liver function tests
Data on liver function test (LFT) proteins were available
for 87% of the study sample (for details, see Rahmioglu
et al. [22]). Abnormal liver function as assessed by LFTs
can be used to assist diagnosis of non-alcoholic fatty
liver disease (NAFLD) [23]. Serum concentrations of ala-
nine transaminase (ALT), alkaline phosphatase (ALK),
total bilirubin (BIL) and γ-glutamyl transpeptidase
(GGT) were used in this study as markers of liver func-
tion. Of the four tests, ALT is the most sensitive marker
for liver cell damage (as a consequence of disease or
drug use), while ALK and GGT are more indicative of
cholestatic injury and BIL, haem catabolism [24, 25].
The upper limit of normal threshold used for each pro-
tein were: ALT: 39.4 IU/L [26], ALK: 81 IU/L (taken as
the 75% percentile of the sample distribution), BIL: 17.1 -
μmol/L [27], GGT: 33 IU/L [28].
Statistical analyses
Validation sample
Multiple regression analyses [10,11,15] and indices of
adiposity were assessed [8] to address two questions re-
lating to the estimation of total abdominal visceral fat
using DXA adiposity and a range of anthropometric
measures: 1) which of these predictive models for the
“gold standard” CT measure of visceral fat, best fit our
validation sample of 54 females; and 2) in relation to
previous discussions [8], can visceral fat be reliably esti-
mated based upon anthropometry alone. CT and DXA
scans for the same individuals were date-matched to be-
tween 0.23 - 2.3 years of one another. The difference in
scan date for the validation sample was included in all
visceral fat regression models as a nuisance factor. A
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predicted VAT error term was constant or varied across
the range of CT-measured VAT area.
Heritability analysis (study sample)
The classical twin model was used to estimate the rela-
tive influence of genetic and environmental factors upon
individual variation about the visceral fat sample mean
[29]. Using variance components analysis, the total
phenotypic variance was partitioned into estimates of
the additive polygenic (A), dominant (D) genetic and
shared familial environment (common; C) and unique to
the individual, environmental and measurement error
(E) components using genetically informative data. The
model assumes no epistasis, gene-environment correl-
ation or interactions and that shared environmental
factors are not confounded by zygosity (the equal envi-
ronments assumption). Provided these assumptions
hold, on the basis that MZ twins share identical genes
and DZ twins share, on average, half their segregating
genes, twin data can be used to infer heritability and
shared familial estimates. Maximum likelihood models
were implemented using Mx [30].
In addition to the univariate heritability analysis, we
also conducted a bivariate variance components analysis
between the realised estimate of VAT area and total ab-
dominal fat as an indirect means to further validate the
proxy measure of VAT. Bivariate analysis facilitates a test
of genetic correlation between two variables, but also
whether each variable has a specific genetic component
that is not shared by the two traits. We used the specific
test to assess if there was evidence for a genetic compo-
nent that is unique to VAT area and not shared with
DXA total abdominal fat [30].
Morbidity association with adiposity (study sample)
Type 2 diabetes, hypertension and liver function were
associated with the different measures of adiposity vari-
ables and age using logistic regression using a cross-
sectional study design. By contrast, prospective incident
subclinical atherosclerosis (cIMT) was modelled using
Cox regression and baseline measures of visceral fat
taken on average 10 years (range 5–16 years) previously.
Since there was no baseline examination of cIMT, we
could not exclude the small proportion of individuals
who may have already developed subclinical atheroscler-
osis at baseline. To the extent this was true, the study
design for these individuals would have been also cross-
sectional rather prospective.
LFTs were performed using blood samples collected at
the same visit as the DXA scan. The mean, standard de-
viation and median were all examined to identify poten-
tial batch effects across years, but no obvious trend was
identified. Therefore the year of visit was categorised asquintiles and included in all analyses as a categorical
confounding variable.
Co-linearity between the explanatory measures of VAT
area, DXA total abdominal fat, BMI and age was
assessed using pairwise correlations and residuals ana-
lysis [31,32]. A variance inflation factor (VIF) was calcu-
lated for these data, with a score of ≥ 10 sometimes used
as a (conservative) threshold indicator for potentially
problematic co-linearity between model explanatory var-
iables [32]. To assess consistency of results, the multiple
regression analyses were repeated using random sub-
groups of data and using quantitative traits for all sub-
jects, where morbidity had been defined using a
quantitative trait threshold (i.e. systolic and diastolic
blood pressure and LFTs).
Parsimonious best-fit multiple regression models for
morbidity were identified by a) using a likelihood ratio test
(LRT) to assess the contribution of each explanatory
variable to the full model; b) assessing model fit using
pseudo-R2 for T2D, HTand LFTs and the Wald statistic for
incident cIMT, and c) the implementation of a linear resid-
uals analyses [31] to assess whether adiposity measures are
independent of morbidity, when conditioned upon on vis-
ceral fat. For example, to assess if VAT completely mediates
the association between BMI and T2D, secondary residuals
analysis involved taking the residuals for T2D on the logit
scale and the ordinary least squares residuals for BMI, both
with respect to VAT area and age. Ordinary least squares
(OLS) residuals for DXA total abdominal fat were also
taken with respect to VAT area and age. The secondary re-
siduals analysis was implemented using linear regression of
T2D residuals upon BMI and DXA residuals. No evidence
of association between residuals would imply that BMI/
DXA association with morbidity is primarily mediated via
VAT area, while a significant residual association demon-
strates either that BMI/DXA are associated with morbidity
through a path not mediated by VAT area, or that the para-
metric assumptions of the association models are false.
To facilitate assessment of the relative importance of adi-
posity measures associated with morbidity, unadjusted and
adjusted odd ratios (OR) results are presented for VATarea
(cm2), DXA total abdominal fat (kg) and BMI (kg/m2). To
facilitate comparison between the different adiposity units,
all adiposities were standardised for the regression analyses.
Robust standard errors were estimated by grouping twin
pairs using the cluster option in Stata to account for intra-
family relatedness. All statistical analyses were performed
using Stata version 11.1 (StatCorp, Texas).
Results
Estimation of visceral fat (validation sample)
Descriptive statistics for anthropometric and body com-
position for the validation and study samples are
presented in Table 1. All subjects were female and over
Table 1 Validation and study sample characteristics
Validation sample (n = 54) Study sample (n = 3457)
Mean SD Min. Max. Mean SD Min. Max.
Age (years) 60.4 6.1 49.3 72.8 54.2 8.3 40.0 79.5
Weight (kg) 65.7 9.4 48.4 87.4 66.6 11.8 35.6 139.5
Height (m) 1.62 0.06 1.48 1.75 1.62 0.06 1.39 1.82
Waist circumference (cm) 88.0 9.9 66.6 111.2 81.0 11.0 55.0 134.0
Sagittal depth (cm) 21.8 3.2 15.9 31.1 - - - -
Scan difference (years) 1.3 0.8 0.2 2.5 - - - -
BMI (kg/m2) 25.1 3.8 19.2 33.8 25.6 4.5 15.1 51.7
Total abdominal fat (kg) 1.40 0.62 0.24 3.08 1.44 0.61 0.14 3.94
VAT area (cm2) 127.8 52.1 37.7 279.5 144.6 49.6 37.7 347.4
Diastolic BP (mmHG) 77.3 8.3 61.0 95.5 75.9 8.9 47.5 108.0
Systolic BP (mmHG) 122.0 11.5 92.0 151.0 123.1 14.7 86.5 189.0
cIMT 0.68 0.08 0.53 0.82 0.67 0.11 0.30 1.11
ALT 23.9 11.8 3.0 68.0 26.7 11.4 2.5 217.3
ALK 64.8 19.0 26.0 114.0 71.2 18.2 23.5 218.9
BIL 9.5 3.7 5.7 23.5 8.7 3.0 1.0 30.5
GGT 30.3 17.4 12.0 65.3 27.9 21.7 3.0 359.0
Age, weight, height, body fat distribution and intermediate quantitative traits used to define clinical morbidity. Waist circumference for the validation sample is
based upon the transverse circumference of CT body scan image at the waist, while the study sample is a tape measurement taken at the same time as the DXA
scan. Abbreviations: ALT, alanine transaminase, ALK, alkaline phosphatase, BIL, bilirubin, BP, blood pressure, cIMT, carotid intima-media thickness, GGT, gamma-glutamyl
transpeptidase, SD, standard deviation (between family).
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BMI, DXA total abdominal fat, blood pressure, cIMT, liver
function tests and visceral fat do not statistically differ be-
tween the two samples, although the mean age for the val-
idation sample was six years older (p = 6.5 × 10-11) with a
larger waist circumference (p = 2.05 × 10-6) than the study
sample. The study sample prevalence and 95% confidence
interval for morbidity related to the quantitative traits
presented in Table 1 were as follows: T2D 0.046 (0.04-
0.05), HT 0.08 (0.07-0.09), cIMT 0.27 (0.24-0.30), ALT
0.22 (0.21-0.24), ALK 0.27 (0.26-0.29), BIL 0.02 (0.02-0.03)
and GGT 0.20 (0.18-0.21).
The Pearson product moment correlation coefficients
(r) between the different adiposity measures and CT mea-
sured VAT area for the validation sample are presented in
Table 2. CT-VAT area was most strongly correlated with
CT-measured body cavity cross sectional area (r = 0.85),
sagittal depth (r = 0.84) and tape-measured waist circum-
ference (r = 0.86) and DXA total abdominal fat (r = 0.79).
Consistent with these data, we observed that reported
models of visceral fat in the literature, whether linear re-
gressions or derived anthropometric indices, all attempt to
capture information about the body cavity volume (or area)
in relation to the subcutaneous volume [8,10,11,15]. We
used this insight to guide our choice of linear regression to
estimate CT-measured visceral fat.
Although the DXA scans were collected between 0.23 –
2.3 years after the CT scans for the validation sample, noevidence was observed for significant change in weight in
these individuals nor was change in weight correlated with
time lapse between scan dates (data not shown).
Table 3 presents the results for three previously pub-
lished DXA-based regression models and anthropometric
indices for estimating visceral fat, applied to the TwinsUK
CT validation sample. The best-replicated regression
models included DXA trunk fat and sagittal depth (R2 ≈
0.8), while a combination of DXA and skin fold was less
predictive of visceral fat. The best individual indices were
functions of sagittal depth (SD), SFW, TID and TED (r ≥
0.85, equivalent to r2 ≥ 0.72). We note that the most repro-
ducible indices of visceral fat all relate to body cavity CSA.
By assuming body cavity CSA takes the form of an ellipse,
we estimated this as body cavity CSA = π x (SD – 2SFW) ×
TID for our validation sample.
In modelling CT-measured VAT area, the best fit and
most interpretable model included a combination of
measures for DXA abdominal fat, body cavity cross sec-
tional area (estimated using the ellipse formula above)
and waist circumference (Table 4, Model 0), which to-
gether explained 91% of the variance in CT-measured
VAT area (R2 = 0.91). However, since sagittal depth was
not available for our study sample for which we wished
to estimate VAT, we also assessed a model including
only DXA total abdominal fat, tape-measured waist cir-
cumference and age. For this (Table 4, Model 1) we
obtained a model with an R2 of 0.83 with the following
Table 2 Validation sample (n = 54) correlation coefficients between CT visceral adipose fat (VAT) area, anthropometric
and abdominal fat measures
VAT BC Sub.CSA Total CSA SD WC TID TED SFW DXA BMI
BC 0.85
Sub. CSA 0.58 0.44
Total CSA 0.81 0.80 0.90
SD 0.84 0.80 0.84 0.96
WC 0.86 0.77 0.83 0.94 0.94
TID 0.66 0.72 0.46 0.67 0.61 0.65
TED 0.66 0.56 0.89 0.87 0.82 0.85 0.62
SFW 0.43 0.26 0.83 0.69 0.66 0.67 0.17 0.88
DXA 0.79 0.56 0.68 0.74 0.76 0.77 0.56 0.75 0.6
BMI 0.71 0.60 0.80 0.84 0.83 0.82 0.57 0.85 0.72 0.79
Weight 0.67 0.64 0.77 0.84 0.76 0.81 0.69 0.88 0.68 0.69 0.86
All measures presented here are based upon CT scan images apart from DXA total abdominal fat, BMI and weight. Abbreviations and units: BC, body cavity area
(cm2), BMI, body mass index (kg/m2), CSA, body cross-sectional area (cm2) at L4:L5, DXA, DXA-measured total abdominal fat (kg), SD, sagittal depth (cm), Sub.CSA,
subcutaneous cross sectional area, SFW, subcutaneous fat width (cm), TED, transverse external diameter (cm), TID, transverse internal diameter (cm), VAT, visceral
adipose tissue (cm2), WC, waist circumference (cm) derived from the CT-image, weight (kg).
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inal fat mass) + 40.8(waist circumference) + 1.4(age) using
standardised explanatory variables and no intercept term.
For this estimate, a Bland-Altman analysis showed no
evidence of heteroscedascity across the full range of CT-
measured VAT area, with only 2 out of 54 (3.7%) values
with a difference outside the 95 limits of agreement (the
mean difference ± twice the standard deviation of the dif-
ference between the two measures).
In relation to efforts attempting to estimate visceral fat
using only anthropometric measures [8,33], we also
obtained a highly explanatory model (R2 = 0.86) with a
linear equation using only two CT measures of body
cavity CSA (estimated as an ellipse) and waist circumfer-
ence (Table 4, Model 2). This figure rose to R2 = 0.89
using body cavity components SD, SFW and WC as ex-
planatory variables for CT VAT area (data not shown).
Body cavity CSA results are presented, as this model is
more interpretable, while the model including SD, SFW
and WC yields a negative beta coefficient for SFW due
to co-linearity. Again, these simple anthropometric
models could not be used for the study sample however,
as sagittal depth was not recorded along with DXA scan
for these subjects.
In addition to these validation models, we indirectly
assessed the validity of our study sample estimates of
visceral fat by making two observations:
1. Realised estimates of VAT area (VATModel1 and
VATModel2) for the validation sample were equally or
more strongly correlated with VATCT (r = 0.89 and r =
0.93) than DXA total abdominal fat (r = 0.88 and r =
0.70, respectively);2. Bivariate variance component analysis between
VATModel1 and DXA total abdominal fat provided
strong statistical evidence (Δχ21 = 43.7, p = 4x10
-11) for
a specific heritable component that was unique to
VATModel1 and not shared with DXA total abdominal
fat (data not shown).
Heritability (study sample)
The data provided a narrow sense heritability estimate
of 0.58 (95% CI: 0.51-0.66) and a familial environmental
effect of 0.24 (95% CI: 0.17-0.30) for VAT area (Table 5),
with the best fit to the data being the ACE model, in-
cluding additive polygenic (A), common familial (C) and
unique environmental (E) components.
Visceral fat as a risk factor of morbidity (study sample)
For the study sample we estimated visceral fat as a linear
function of DXA total abdominal fat, waist circumfer-
ence and age (Model 1, Table 4). Although a model in-
cluding DXA total abdominal fat, waist circumference
and estimated body cavity area was a better fit (Model 0,
Table 4), we used Model 1 as we did not have a measure
of sagittal depth for the study sample subjects required
to estimate body cavity area from the DXA images.
The correlations between study sample explanatory
variables are presented in Additional file 1: Table S1. As
a function of these variables, VAT area is most strongly
correlated with waist circumference and DXA total ab-
dominal fat. While the univariate odd ratios for VAT
area, DXA abdominal fat and BMI were all significantly
associated with each morbidity (Tables 6, 7, 8 and 9),
VAT area was most consistently and strongly associated
with four morbidity traits - T2D, HT, cIMT and ALT.
Table 3 Visceral adipose tissue area (VAT area) linear
model estimates and correlational indices
Model Reported
R2
TwinsUK
R2
A
Snijder et al.
(2002) [11]
DXA trunk fat + sagittal depth 0.74 0.80
DXA trunk fat + abdominal
circumference
0.71 0.78
Treuth et al.
(1995) [15]
Sagittal depth + age + waist
circumference +% DXA trunk fat
0.81 0.79
Hill et al.
(2007) [10]
DXA + skin fold 0.68 0.65
B Index Reported r TwinsUK
Bertin et al.
(2002) [8]
r
Abdominal fat mass (kg) 0.57 0.79
Thigh fat mass (kg) 0.06* -
Abdominal fat mass/thigh fat
mass
0.75 -
Abdominal fat mass/SFW 0.83 0.58
TED (cm) 0.54 0.61
TID (cm) 0.9 0.61
SFW (cm) −0.23* 0.28
(SD)(TID) 0.89 0.87
(SD)(TID)/height 0.91 0.86
(SD)(TID)/BMI 0.66 0.49
(SD-SFW) 0.86 0.89
(SD-SFW)(TID) 0.92 0.79
(SD-SFW)(TID)/height 0.94 0.87
Previously reported models in the literature were applied to the TwinsUK
validation sample of CT-measured VAT area (n = 54) and the coefficient of
determination (R2) is presented for each study as an indication of the
proportion of VAT variance explained by the model. (A). The Pearson product–
moment correlation coefficients between CT-measured VAT area and adiposity
indices described in Bertin et al. (2002) were also calculated for the TwinsUK
validation sample (B). Note that the reported linear models all replicate using
TwinsUK and that highest correlational indices (r > 0.85) for VAT area were all
anthropometric measures that relate to size of the body cavity area. Skin fold
was estimated using the formula SFW = (TED – TID)/2 applied to DXA data, as
calliper skin fold measure was not taken for the TwinsUK study. Asterisks in
table B indicate the reported correlation coefficient does not differ
significantly from zero (at threshold α = 0.05). Abbreviations: DXA, dual-energy
X-ray absorptiometry, SD, sagittal depth, SFW, subcutaneous fat width, TED,
transverse external diameter, TID, transverse internal diameter.
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sistent with visceral fat entirely mediating the association
with other measures of adiposity (BMI and total abdom-
inal fat), but this was not true for the liver function tests
ALK, BIL and GGT (details provided in supplementary
Tables online).
For type 2 diabetes, while the univariate ORs for the 3
adiposity measures were all associated with T2D
(Table 6A), visceral fat and age provided the best-fit
multiple regression model (pseudo-R2 = 0.08, Table 6B
and LRT, Additional file 1: Table S2), with an adjusted
OR of 2.08 (95% CI 1.76 – 2.47) per standard deviationincrement in VAT area including age. Removing VAT
area from the full model resulted in a significant decline
in model fit (LRT χ21 = 14.4, p = 1E-04), while the re-
moval of DXA total abdominal fat and BMI, either indi-
vidually or together (χ22 = 1.9, p = 0.39) did not reduce
the model fit (Additional file 1: Table S2).
Hypertension was equally strongly associated with
VAT area, DXA abdominal fat and BMI for univariate
analyses (Table 7A), but visceral fat and age provided the
best-fit multiple regression model (pseudo-R2 = 0.10,
Table 7B and LRT, Additional file 1: Table S4), with an
adjusted OR of 1.90 (95% CI 1.60 – 2.25) per standard
deviation increment in VAT area including age. Remov-
ing VAT area from the full model resulted in a nominal
decline in model fit (LRT χ21 = 7.1, p = 0.01), whilst the
removal of DXA total abdominal fat and BMI, either in-
dividually or together (χ22 = 1.99, p = 0.37) did not reduce
the model fit (Additional file 1: Table S4).
The prospective analysis of subclinical atherosclerosis
had a median follow up time of 9.7 years, during which
a total of 221 (27%) individuals were classified as sub-
clinically atherosclerotic. Univariate Cox proportional
hazard models showed all three measures of adiposity
and age at baseline to be associated with incident cIMT
(Table 8A), with VAT area (χ21 = 43.8) and age (χ
2
1 = 40)
providing the best-fit parsimonious model (Table 8B).
DXA and BMI could be dropped from the full model
with no nominal (χ22 = 5.7, p = 0.06) deterioration in
model fit (Additional file 1: Table S6).
All LFT protein serum levels were positively associated
with measures of adiposity (Table 9), except for bilirubin,
which was negatively associated. VAT area remained as-
sociated with alanine transaminase (ALT) when condi-
tioned upon DXA total abdominal fat and BMI, while
VAT area and DXA were still associated with ALK, BIL
and GGT conditional upon BMI (Table 9 and related
Additional file 1: Tables S8-S15). Removing VAT area
from the full model for ALT resulted in a significant de-
cline in model fit (LRT χ21 = 19.6, p = 1E-05), while the
removal of DXA total abdominal fat and BMI, either
individually or together (χ22 = 1.56, p = 0.46) did not
(Additional file 1: Table S8).
The estimated variance inflation factor (VIF) between
VAT area and DXA abdominal fat, BMI and age was
8.84. Analyses repeated using subgroups of data and
analyses using underlying quantitative traits for HT,
ALT, ALK, BIL and GGT all provided qualitatively the
same association results (data not shown).
Discussion
This study shows that DXA and anthropometric mea-
sures can be used to derive reliable estimates of visceral
fat and provides evidence that visceral fat - independent
of BMI and total abdominal body fat - is a risk factor for
Table 4 Linear regression models for CT visceral adipose fat (VAT) area using the validation sample (n = 54)
VAT model Measure β SE t p value
95% CI Model
Lower Upper R2
A Model 0: 0.91
Combination of DXA & anthropometric measures DXA abdominal fat 20.1 3.4 5.9 2 × 10-9 13.2 27.0
BC CSA 32.4 4.5 7.2 4 × 10-13 23.2 41.6
WC 11.1 5.6 2.0 2 × 10-2 -0.3 22.4
B Model 1: 0.83
Combination of DXA & anthropometric measures DXA abdominal fat 10.1 4.8 2.1 0.04 0.31 19.9
WC 40.8 5.7 7.2 3 × 10-13 29.2 52.3
Age 1.4 0.5 2.6 0.01 0.3 2.4
C Model 2: 0.86
Anthropometric measures only BC CSA 25.5 5.6 4.6 2 × 10-6 14.1 36.8
WC 30.5 5.5 5.6 1 × 10-8 19.4 41.6
Model 0: combination of DXA and anthropometric measures guided by previously published models presented in Tables 3A (A); Model 1: combination of DXA
and anthropometric measures restricted to DXA total abdominal fat, WC and age that were also available for the study sample (B); Model 2: using anthropometric
measures only (C). BC CSA was estimated using BC = (π × (SD–2SFW) × TID) from the CT images at intervertebral disc L4:L5 as described in Methods. Note that for
Model 2, using these explanatory variables instead of BC CSA, yields equally good or better prediction of VAT area (R2 = 0.89), but the model is less interpretable
with a negative beta coefficient for SFW. Abbreviations: BC, body cavity, CSA, cross sectional area, SD, sagittal depth, SFW, subcutaneous fat width, TED, transverse
external diameter, TID, transverse internal diameter.
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and ALT liver function. Validation sample explanatory
models were able to explain >80% of the variance in CT-
measured visceral fat. A combination of DXA and an-
thropometric measures (R2 = 0.91) or models including
only anthropometric measures (R2 = 0.86 – 0.89), both
provided equally good estimates of visceral fat. We ob-
tain a heritability of 58% for visceral fat, which is con-
sistent with familial studies that report within the region
of 48-57% [34-37] and using a twin design, confirms for
the first time that the observed familial component is
also partly due to shared familial environment (24%).
Our results confirm that visceral fat is the single most
important measure of adiposity for risk of type 2 dia-
betes. In large DXA resources, such as the one used byTable 5 Visceral adipose tissue (VAT) area estimate of heritab
Model −2 LL df AIC Δdf
ACE 51399.9 4737 41925.9 -
AE 51438.7 4738 41962.7 1
CE 51608.4 4738 42132.4 1
Full (ACE) and nested (AE and CE) model estimates are presented. Nested sub-mod
component (model CE) and the shared familial environmental component (model A
is the best-fit model, since the more parsimonious sub-models do not fit the data a
best model fit. Abbreviations: -2 LL: minus twice the log-likelihood; AIC: Akaike’s Inf
polygenic variance component, C – common familial environment, E – unique enviLeslie et al. (2010) [38], it would be interesting to ascer-
tain whether the risk of developing diabetes is better
predicted if a DXA-based estimate of visceral fat was
used rather than using DXA total abdominal fat.
Visceral fat mediates all associations between hyper-
tension and adiposity variables for these cross sectional
data. Similarly, in a longitudinal study, Hayashi et al.
(2004) [39] showed that only visceral fat is significantly
associated with hypertension, when visceral fat is ad-
justed for other adiposity measures (e.g. BMI, waist cir-
cumference or abdominal subcutaneous fat). Visceral
and subcutaneous adiposity both contribute to the
prevalence of hypertension, but when adjusted for BMI
or waist circumference, subcutaneous fat is no longer as-
sociated with hypertension [37]. This further illustratesility (h2) and model fit statistics (n = 3457)
Δχ2 p value h2 95% CI
- - A 0.58 (0.51-0.66)
C 0.24 (0.17-0.30)
E 0.18 (0.16-0.20)
39 4.70x10-10 A 0.83 (0.81-0.84)
C - -
E 0.18 (0.16-0.19)
209 2.92x10-47 A - -
C 0.62 (0.59-0.64)
E 0.38 (0.36-0.41)
els test the hypothesis that the estimated additive polygenic genetic variance
E) do not contribute to the observed phenotypic variance. The full ACE model
s well (p < < 0.05). The model with the lowest AIC fit statistic also indicates
ormation Criterion; Δχ2: likelihood ratio chi square statistic; A – additive
ronmental variance (and measurement error) specific to the individual.
Table 6 Type 2 diabetes (T2D) and adiposity
Type 2 diabetes OR SE z p value
95% CI Model
Lower Upper pseudo-R2
A
VAT 2.17 0.18 9.5 <2 × 10-16 1.85 2.54 0.07
DXA abdominal fat 1.86 0.13 8.6 <2 × 10-16 1.61 2.14 0.05
BMI 1.66 0.12 7.2 2 × 10-13 1.45 1.91 0.04
Age 1.05 0.01 4.3 8 × 10-6 1.03 1.07 0.02
B
VAT 2.08 0.18 8.5 <2 × 10-16 1.76 2.47
0.08
Age 1.02 0.01 2.0 0.05 1.00 1.05
The study sample prevalence (females > = 40 years) estimate for T2D = 0.05. Logistic regressions (n = 2964) presenting unadjusted odds ratios (OR) (A) and best-fit
multiple regression model with adjusted OR for visceral adipose fat (VAT) area and age (B). For evidence of the presented best-fit model and an analysis of
residuals to account for co-linearity between adiposity variables, see Additional file 1: Tables S2 and S3, respectively. Explanatory variables VAT, DXA and BMI are
all standardised, implying a change in odds ratio per unit SD change. For logistic regression, the pseudo-R2 model-fit statistic is analogous (but not directly
comparable) to the ordinary least squares regression R2 statistic, known as the coefficient of determination. While R2 can be interpreted as the proportion of
variance explained by the model, pseudo-R2 is loosely interpreted as the proportion of variation in risk liability explained by the model (StatCorp, Texas).
Abbreviation: CI - confidence interval.
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that appears to determine the risk of morbidity.
The analysis of incident subclinical atherosclerosis is
consistent with cross-sectional studies that show associ-
ation between atherosclerosis, total abdominal fat [40]
and visceral fat [41,42]. Here we provide additional evi-
dence that total abdominal and visceral fat accumulation
precedes atherosclerosis.
The LFT protein results suggest that liver function de-
teriorates with increasing visceral adiposity with VAT
area positively associated with ALT, ALK and GGT. By
contrast, the inverse relationship between visceral fat
and bilirubin is consistent with the inverse association
between bilirubin, insulin resistance [43] and GGT activ-
ity [44]. In particular, of the four tests, the linear associ-
ation between ALT and adiposity is specifically mediated
via visceral fat, while for ALK, BIL and GGT there isTable 7 Hypertension and adiposity
Hypertension OR SE z
A
VAT 2.08 0.16 9.5
DXA abdominal fat 1.77 0.14 7.4
BMI 1.77 0.13 7.7
Age 1.07 0.01 6.4
B
VAT 1.90 0.17 7.4
Age 1.04 0.01 4.0
The study sample prevalence estimate (females > = 40 years) for hypertension = 0.0
multiple regression model including visceral adipose fat (VAT) area and age (B). For
account for co-linearity between adiposity variables, see Additional file 1: Tables S4
standardised, implying a change in odds ratio per unit SD change. Year of visit was
confounding variable. See Table 6 legend for an explanation of pseudo-R2. Abbreviaonly evidence to suggest this is the case for abdominal
fat per se. The visceral adipose depot is thought to be
the major source of elevated fatty acid delivered to the
liver via the portal vein and it is possible that visceral fat
acts as a marker of hepatic fat content [45]. Hepatic fat
accumulation is known to impair insulin signalling in
hepatocytes [46,47] and “pathway selective insulin resist-
ance” [48] maybe pivotal in the transition from normal
to impaired fasting glucose states. It has been
hypothesised that non-alcoholic fatty liver (NALFD) may
play a mediatory role in the pathology of CVD [49].
The relative strengths and limitations of this study
were: 1) Adiposity inferences are restricted to middle-
aged Caucasian women with a BMI ≤ 35. The VAT area
estimates for the study sample included the 4% of fe-
males with a BMI > 35, which was outside the validation
sample data range. Although these estimates strictlyp value
95% CI Model
Lower Upper pseudo-R2
<2 × 10-16 1.79 2.42 0.08
6 × 10-14 1.53 2.07 0.05
6 × 10-15 1.53 2.05 0.06
6 × 10-11 1.05 1.09 0.05
9 × 10-14 1.60 2.25
0.10
4 × 10-5 1.02 1.07
8. Logistic regressions (n = 2032) showing unadjusted ORs (A) and best fit
evidence of the presented best-fit model and an analysis of residuals to
and S5, respectively. Explanatory variables VAT, DXA and BMI are all
categorised as quintiles and included in all HT analyses as a categorical
tion: CI, confidence interval.
Table 8 Sub-clinical atherosclerosis and adiposity
Carotid intima-media
thickness HR SE z p value
95% CI Model fit (Wald)
Lower Upper χ2 df p value
A
VAT 1.50 0.09 6.6 2 × 10-11 1.33 1.69 43.8 1 4 × 10-11
DXA abdominal fat 1.29 0.07 4.5 4 × 10-6 1.16 1.45 20.0 1 8 × 10-6
BMI 1.39 0.08 5.5 2 × 10-8 1.23 1.55 30.5 1 3 × 10-8
Age 1.08 0.01 6.3 1 × 10-10 1.05 1.10 40.0 1 3 × 10-10
B
VAT 1.36 0.10 4.4 5 × 10-6 1.19 1.56 59.6 2
1 × 10-13
Age 1.06 0.01 5.0 3 × 10-7 1.04 1.09
Cox proportional hazards regression (n = 801) showing unadjusted ORs (A) and best-fit model including visceral adipose fat (VAT) area and age (B). For evidence
of the presented best-fit model and an analysis of residuals to account for co-linearity between adiposity variables, see Additional file 1: Tables S6 and S7,
respectively. The study sample prevalence estimate (females > = 40 years) for sub-clinical atherosclerosis at follow-up was 0.27 (average time from baseline to
follow up was 9.95 years, range 5–16 years). Explanatory variables VAT, DXA and BMI are all standardised, implying a change in hazard ratio per unit SD change.
For Cox proportional hazards, the Wald model-fit statistic is presented to indicate the best model fit (StatCorp, Texas) that predicts onset of sub-clinical
atherosclerosis (carotid intima-media thickness, cIMT). Abbreviation: CI - confidence interval.
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did not qualitatively alter the results for the heritability
or morbidity association (data not shown) and so these
individuals were retained. 2) We have shown that sagittal
depth is an extremely useful yet simple anthropometric
measurement to estimate the body cavity area. When
used in combination with the subcutaneous fat width,Table 9 Liver function tests (LFTs) and adiposity
Liver function tests OR SE z
ALT (0.22)
VAT 1.75 0.09 10
Age 1.02 0.01 2.
ALK (0.27)
VAT 1.28 0.14 2.
DXA abdominal fat 1.26 0.13 2.
Age 1.06 0.01 9.
BIL* (0.02)
VAT 0.62 0.10 −3
BIL* (0.02)
DXA abdominal fat 0.67 0.10 −2
GGT (0.20)
VAT 1.25 0.14 1.
DXA abdominal fat 1.36 0.15 2.
Age 1.02 0.01 2.
Best-fit multiple regression models for LFTs are presented for the logistic regression
tissue (VAT) area, DXA total abdominal fat, body mass index (BMI) and age. Prevale
(see Methods). Explanatory variables VAT, DXA and BMI are all standardised, implyin
quintiles and included in all LFT analyses as a categorical confounding variable. *No
and VAT area predict BIL equally well. Including both measures in this model provid
Additional file 1: Table S1). For evidence of the presented best-fit model and analys
four LFTs, see Additional file 1: Tables S8-S15. Abbreviations: ALT, alanine transamin
gamma-glutamyl transpeptidase.this measure contributes to a very good estimation of
visceral fat (R2 approximately 90%). Where DXA is not
available, sagittal depth, waist circumference and sub-
cutaneous fat width could therefore be measured to
quickly and inexpensively estimate a person’s visceral fat
content with just a tape measure and skin callipers. Not
having sagittal depth for the study sample limited ourp value
95% CI Model
pseudo-R2Lower Upper
0.09
.9 <2 × 10-16 1.58 1.93
9 0.004 1.01 1.03
0.09
4 0.02 1.05 1.58
3 0.02 1.03 1.54
8 <2 × 10-16 1.05 1.07
0.054
.0 0.003 0.46 0.85
0.049
.7 0.01 0.50 0.90
0.06
9 0.05 1.00 1.56
8 0.01 1.10 1.70
7 0.007 1.00 1.03
models (n = 3014) including potential explanatory variables visceral adipose
nce for upper limit of normal threshold for each assay is indicated in brackets
g a change in odds ratio per unit SD change. Year of visit was categorised as
te that two multiple regression models are presented for BIL, since both DXA
es uninterpretable ORs due to co-linearity between the variables (see
is of residuals to account for co-linearity between adiposity variables for the
ase, ALK, alkaline phosphatase, BIL, bilirubin, CI, confidence interval, GGT,
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indicated by the best anthropometric validation sample
estimate (Model 2) predicting VAT area as well or better
than a combination of DXA total abdominal fat, waist
circumference and age (Model 1); 3) Arising from the
second limitation, although our prediction of visceral fat
was still valid [32], co-linearity between model explana-
tory variables – in particular VAT area and DXA total
abdominal fat – meant that adjusted Odds Ratios for
risk factors were not interpretable. Instead, conditional
independence structures were assessed using residuals
analysis. This allowed us to eliminate the possibility of
causal relationships between adiposity variables and
morbidity, except those mediated by visceral fat; 4) The
twin-based heritability estimate presented here is likely
to be an under-estimate, since random measurement
error is included in the denominator of the heritability
ratio estimate and the study sample estimate of visceral
fat is known to account for approximately only 83% of
CT-measured VAT area; 5) The study design for incident
subclinical atherosclerosis was not strictly prospective,
since no baseline measure of cIMT was taken to facili-
tate the exclusion of potential baseline cases. Where un-
detected baseline cases exist, the study design is cross
sectional; 6) Inclusion criteria for the validation sample
were that study subjects were female, over 40 and had
both DXA and CT scans within 2 years of one another.
Although not measured the same day, time between
visits was included in analyses as a confounding variable
and Bland-Altman plots revealed no bias in the relation-
ship between predicted and CT-measured visceral fat
values. More importantly, no significant weight gain was
observed between the collection of CT and DXA mea-
surements and small fluctuations in weight were not
correlated with the time lapse between scan dates.
This study shows that, where a direct measure of vis-
ceral fat is unavailable, using an indirect estimate of vis-
ceral fat (even without a measure of subcutaneous fat) is
more predictive of morbidity than total abdominal fat.
Our study suggests that both DXA body fat composition
and anthropometric measures of body cavity volume
alone can provide reliable estimates of abdominal vis-
ceral fat.
In conclusion, we demonstrate that DXA-based mea-
sures of visceral fat can be both reliable and valid and are
a cheaper and less intrusive alternative to other methods
such as MRI and CT to estimate adiposity. Visceral fat is
not only strongly associated with morbidity, but also ap-
pears to mediate the association between morbidity and
other measures of adiposity for type 2 diabetes, hyperten-
sion and elevated alanine transaminase serum levels. This
is consistent with hypotheses that suggest excess visceral
fat accumulation is causally related to cardiovascular and
metabolic disease.Additional file
Additional file 1: Table S1. Study sample (n = 3457) correlation and
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(T2D) multiple regression analyses. Table S3. Residuals analysis for type 2
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Residuals analysis for carotid intima-media thickness (cIMT). Table S8.
Multiple regression analyses for alanine transaminase (ALT).
Table S9. Residuals analysis for the quantitative trait (QT)/assay for
alanine transaminase (ALT). Table S10. Multiple regression analyses for
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